Abbas Ebrahimi‐Kalan
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Oncology top 5%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- RNA Interference and Gene Delivery 7
-
- Spinal Cord Injury Research 7
- Multiple Sclerosis Research Studies 4
- Co-authors
- Rana Jahanban‐Esfahlan (2 shared papers)Khaled Seidi (2 shared papers)Leila Roshangar (3 shared papers)Tahereh Javaheri (1 shared paper)Payman Zare (1 shared paper)Saeed Kolahian (1 shared paper)Mehdi Jaymand (1 shared paper)Roghayyeh Baghban (1 shared paper)
- Journals
- Advanced Pharmaceutical Bulletin (6 papers)Biomedicine & Pharmacotherapy (4 papers)Journal of Drug Delivery Science and Technology (3 papers)Bioimpacts (3 papers)Life Sciences (3 papers)
- Partner nations
- IranUnited StatesTürkiye
In The Last Decade
Abbas Ebrahimi‐Kalan
60 papers receiving 2.0k citations
Abbas Ebrahimi‐Kalan's Hit Papers
Peers
Comparison fields: 5 of 133
- Cancer Research 395
- Oncology 565
- Immunology 373
- Biomaterials 230
- Molecular Biology 762
Countries citing papers authored by Abbas Ebrahimi‐Kalan
This map shows the geographic impact of Abbas Ebrahimi‐Kalan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abbas Ebrahimi‐Kalan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abbas Ebrahimi‐Kalan more than expected).
Fields of papers citing papers by Abbas Ebrahimi‐Kalan
This network shows the impact of papers produced by Abbas Ebrahimi‐Kalan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abbas Ebrahimi‐Kalan. The network helps show where Abbas Ebrahimi‐Kalan may publish in the future.
Co-authors
The 25 scholars most cited alongside Abbas Ebrahimi‐Kalan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor microenvironment complexity and therapeutic implications at a glance Hit paper breakdown → | 2020 | 1223 |
| 2 | 2018 | 83 | |
| 3 | 2021 | 62 | |
| 4 | 2023 | 55 | |
| 5 | 2017 | 52 | |
| 6 | 2020 | 46 | |
| 7 | 2020 | 30 | |
| 8 | 2020 | 29 | |
| 9 | 2020 | 28 | |
| 10 | 2018 | 26 | |
| 11 | 2017 | 26 | |
| 12 | 2021 | 26 | |
| 13 | 2023 | 25 | |
| 14 | 2018 | 22 | |
| 15 | 2021 | 20 | |
| 16 | 2018 | 18 | |
| 17 | 2019 | 18 | |
| 18 | 2016 | 16 | |
| 19 | 2021 | 14 | |
| 20 | 2020 | 13 |
About Abbas Ebrahimi‐Kalan
Abbas Ebrahimi‐Kalan is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Immunology, Cancer Research and Biomedical Engineering, having authored 69 papers that have together received 2.1k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (8 papers), RNA Interference and Gene Delivery (7 papers), Spinal Cord Injury Research (7 papers), Graphene and Nanomaterials Applications (5 papers), Electrospun Nanofibers in Biomedical Applications (4 papers), Nanoparticle-Based Drug Delivery (4 papers), Multiple Sclerosis Research Studies (4 papers) and Neurological Disorders and Treatments (4 papers). The work is most often cited by research in Cancer Research (395 citations), Oncology (565 citations), Immunology (373 citations), Biomaterials (230 citations) and Molecular Biology (762 citations). Abbas Ebrahimi‐Kalan has collaborated with scholars based in Iran, United States and Türkiye. Frequent co-authors include Rana Jahanban‐Esfahlan, Khaled Seidi, Leila Roshangar, Tahereh Javaheri, Payman Zare, Saeed Kolahian, Mehdi Jaymand, Roghayyeh Baghban, Ahmad Mehdipour and Mohammad Reza Alipour. Their work appears in journals such as Advanced Pharmaceutical Bulletin, Biomedicine & Pharmacotherapy, Journal of Drug Delivery Science and Technology, Bioimpacts and Life Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.